Sprifermin: a recombinant human fibroblast growth factor 18 for the treatment of knee osteoarthritis.

Sprifermin could be one of the most promising DMOADs, especially for cartilage phenotype. Current studies show good tolerability and no safety concerns. Well-designed phase 3 clinical trials are required to examine its effects on symptoms and cartilage loss in knee OA.